Αρχική World News Cancer target missed for 55,000 patients over 6 years

Cancer target missed for 55,000 patients over 6 years

In the last 6 years, almost 55,000 cancer patients should have been diagnosed quicker or started their treatment sooner, according to new calculations from Cancer Research UK released today.

This is because, in England, the NHS has continued to miss its target to treat 85% of cancer patients within 2 months of their urgent suspected cancer referral. A target that exists to ensure that patients are seen, diagnosed and treated quickly.

And this is likely to be the tip of the iceberg, as the figures only capture cancer patients who had an urgent suspected cancer referral. Those diagnosed through a different route – following a routine referral for example – are likely to have waited even longer.

Why is the target consistently being missed?

Though several factors can influence how quickly someone is diagnosed or able to start treatment, the charity’s chief executive, Michelle Mitchell, explains that the impact of COVID-19 and years of workforce shortages and insufficient infrastructure have meant that cancer targets continue to be missed.

The target of 85% hasn’t been met since 2015, and worryingly, figures have been deteriorating year-on-year since 2017. Around 4,000 additional patients needed to be diagnosed and start treatment to hit the target in 2016. And the numbers are mounting – in July of this year, this figure was already around 11,600.

Mitchell urges the Chancellor to use the upcoming Comprehensive Spending Review to provide multi-year investment for the NHS to train more staff and buy more diagnostic equipment, in order to meet waiting time targets, and put the UK on the path towards world-leading cancer survival.

Cancer won’t wait and the time for the Government to fix these chronic issues is now.

– Michelle Mitchell, Cancer Research UK’s chief executive

Despite working as hard as they can, NHS staff and services are constantly on the back foot, particularly as the number of people with cancer continues to grow.

‘For people with cancer every day counts’

Professor Charles Swanton, Cancer Research UK’s chief clinician, said: “Being referred urgently because you might have cancer, receiving a diagnosis and beginning treatment for the disease are hugely anxious times for patients, which are further compounded when there are delays. For people with cancer, every day counts; that is why we have cancer targets.”

He adds that having worked for the NHS for a number of years, it has been hard to watch the continuous deterioration, as well as the anxiety and worsening outcomes this can cause patients.

Cancer survival in England has lagged behind comparable countries for years, and there is a real possibility that it could go backwards for the first time. But this is not inevitable.

Echoing Mitchell’s call to the Chancellor, he said: “The Government has to commit to long term investment in workforce and kit so that we can turn things around and give patients both the care and outcomes they deserve.”

Is the new health and social care levy not sufficient?

The NHS funding announced earlier this month is an important part of helping patients get tests and treatment sooner, but it’s only one piece of the jigsaw.

To improve cancer survival, and meet growing demand for cancer care, the charity says sustained investment in staff and equipment is urgently required.

Join Cancer Research UK and others in calling for more investment in the NHS workforce.

More on this topic



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

2-Year-Boy Is So Excited To See Himself In Disney’s ‘Encanto’

The importance of representation in media has been a growing topic of concern, and companies have responded by adding more diversity to their characters,...

Man Walks Entire Continent To Spread Awareness About Mental Health & Suicide Prevention

Matthew Fennell is walking over 3,000 miles across Australia for an important cause and one that is near and dear to his heart. Last year,...

Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45 Agencies

At just ten years old, Devarjaye “DJ” Daniel has already been through more than most people go through in their entire lives. DJ has been...

Paclitaxel and Carboplatin Not Inferior When Compared with Paclitaxel and Ifosfamide for the Treatment of Patients with Uterine Carcinosarcoma

With regard to overall survival (OS), paclitaxel and carboplatin was not inferior and demonstrated improved progression-free survival (PFS) when compared with paclitaxel and ifosfamide...

Cancer in My Community: Improving Access to Palliative Care in Indonesia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...

Should CAR T Cells Be Used Earlier in People with Non-Hodgkin Lymphoma?

January 13, 2022, by NCI Staff Several approved CAR T-cell therapies work by binding to the CD19 antigen on cancer cells and killing them. Credit: Adapted...